Skip to main content
SpringerLink
Log in

Safety Issues in the Use of Methylphenidate

An American Perspective

  • Leading Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Summary

Methylphenidate is the most widely used psychotropic medication in children in the US. It is both well tolerated and efficacious in the treatment of attention deficit hyperactivity disorder, and is associated with few serious adverse effects. However, the abuse of methylphenidate for the purpose of experiencing a ‘high’ is hazardous. The use of methylphenidate in combination with other medications increases the risk of adverse effects and drug interactions. Good communication between the physician, patient and family, together with monitoring, increases the likelihood that methylphenidate therapy will be effective and have no adverse consequences.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Barkley RA. Attention deficit hyperactivity disorder: a handbook for diagnosis and treatment. New York: Guilford Press, 1990

    Google Scholar 

  2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994

    Google Scholar 

  3. Szatmari P, Offord DR, Boyle MH. Ontario child health study: prevalence of attention deficit disorder with hyperactivity. J Child Psychol Psychiatry 1989; 30: 219–30

    Article  PubMed  CAS  Google Scholar 

  4. Taylor E. On the epidemiology of hyperactivity: attention deficit disorder, clinical and basic research. In: Sagrolden T, Archer T, editors. Hillsdale (NJ): Erlbaum, 1989: 31–52

  5. Wender P. Attention deficit disorder in adults. New York: Oxford Press, 1994

    Google Scholar 

  6. Safer DJ, Zito JM, Fine EM. Increased methylphenidate usage for attention deficit disorder in the 1990s. Pediatrics 1996; 98(6): 1084–8

    PubMed  CAS  Google Scholar 

  7. Drug Enforcement Administration. ARCOS (Automation of Reports and Consolidated Orders Systems) Data Base 1981–1994. Washington, DC: US Department of Justice, 1996

    Google Scholar 

  8. Rappley MD, Gardiner JC, Jetton JR, et al. The use of methylphenidate in Michigan. Arch Pediatr Adolesc Med 1995; 149: 675–9

    Article  PubMed  CAS  Google Scholar 

  9. Shaywitz SE, Shaywitz BA. Increased medication use in attention deficit hyperactivity disorder: regressive or appropriate? JAMA 1988; 260(15): 2270–2

    Article  PubMed  CAS  Google Scholar 

  10. Spencer T, Biederman J, Wilens T, et al. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry 1996; 35(4): 409–32

    Article  PubMed  CAS  Google Scholar 

  11. Evans SW, Pelham WE. Psychostimulant effects on academic and behavioral measures for ADHD junior high school students in a lecture format classroom. J Abnorm Child Psychol 1991; 19: 537–52

    Article  PubMed  CAS  Google Scholar 

  12. Swanson JM, Cantwell DP, Lerner M, et al. Effects of stimulant medication on learning in children with ADHD. J Learn Disabil 1991; 4: 219–230, 255

    Article  Google Scholar 

  13. Kaplan SL, Busner J, Kupietz S, et al. Effects of methylphenidate on adolescents with aggressive conduct disorder and ADHD: a preliminary report. J Am Acad Child Adolesc Psychiatry 1990; 29(5): 719–23

    Article  PubMed  CAS  Google Scholar 

  14. Campbell M, Gonzalez NM, Silva RR. The pharmacologic treatment of conduct disorders and rage outbursts. Psychiatr Clin North Am 1992; 15(1): 69–85

    PubMed  CAS  Google Scholar 

  15. Jacobvitz D, Sroufe LA, Stewart M, et al. Treatment of attentional and hyperactivity problems in children with sympathomimetic drugs: a comprehensive review. J Am Acad Child Adolesc Psychiatry 1990; 29: 677–88

    Article  PubMed  CAS  Google Scholar 

  16. Elia J. Drug treatment for hyperactive children: therapeutic guidelines. Drugs 1993; 46: 863–71

    Article  PubMed  CAS  Google Scholar 

  17. Kelly DP, Aylward GP. Development and behavior, older children and adolescents: attention deficits in school-aged children and adolescents. Pediatr Clin North Am 1992; 39(3): 487–512

    PubMed  CAS  Google Scholar 

  18. Klein RG, Manuzza S. Hyperactive boys almost grown up: III. Methylphenidate effects on ultimate height. Arch Gen Psychiatry 1988; 45: 1131–4

    Article  PubMed  CAS  Google Scholar 

  19. Gadow KD, Sverd J, Sprafkin J, et al. Efficacy of methylphenidate for attention deficit hyperactivity disorder in children with tic disorder. Arch Gen Psychiatry 1995; 52: 444–55

    Article  PubMed  CAS  Google Scholar 

  20. Castellanos FX, Giedd JN, Elia J, et al. Controlled stimulant treatment of ADHD and comorbid Tourette’s syndrome: effects of stimulant and dose. J Am Acad Child Adolesc Psychiatry 1997; 36(5): 589–96

    Article  PubMed  CAS  Google Scholar 

  21. Handen BL, Feldman H, Gosling A, et al. Adverse side effects of methylphenidate among mentally retarded children with ADHD. J Am Acad Child Adolesc Psychiatry 1991; 30(2): 241–5

    Article  PubMed  CAS  Google Scholar 

  22. Schleifer M, Weiss G, Cohen N, et al. Hyperactivity in preschoolers and the effect of methylphenidate. Am J Orthopsychiatry 1975; 45(1): 38–50

    Article  PubMed  CAS  Google Scholar 

  23. Dunnick JK, Hailey JR. Experimental studies on the long-term effects of methylphenidate hydrochloride. Toxicology 1995 Nov 30; 103(2): 77–84

    Article  PubMed  CAS  Google Scholar 

  24. Gross-Tsur V, Manor O, Van der Meere J, et al. Epilepsy and attention deficit hyperactivity disorder: is methylphenidate safe and effective? J Pediatr 1997; 130(1): 6–9

    Google Scholar 

  25. Dulcan MK. Using psychostimulants to treat behavioral disorders of children and adolescents. J Child Adolesc Psychopharmacol 1990; 1(1): 7–20

    Article  PubMed  CAS  Google Scholar 

  26. Wilens TE, Blederman J. Pediatricpsychopharmacology: the stimulants. Psychiatr Clin North Am 1992; 15: 191–222

    PubMed  CAS  Google Scholar 

  27. Hoffman BB, Lefkowitz RJ. Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists. In: Hardman JG, Limbard LE, editors. Goodman and Gilman’s The pharmacological basis of therapeutics. 9th ed. New York: McGraw Hill, 1996: 220

    Google Scholar 

  28. Carter HS, Watson WA. IV pentazocine/methylphenidate abuse: the clinical toxicity of another Ts and blues combination. J Toxicol Clin Toxicol 1994; 32(5): 541–7

    Article  PubMed  CAS  Google Scholar 

  29. McBride MC. An individual double-blind crossover trial for assessing methylphenidate response in children with attention deficit disorder. J Pediatr 1989; 114(5): 902–3

    Google Scholar 

  30. Ahmann PA, Waltonen SJ, Olson KA, et al. Placebo-controlled evaluation of Ritalin side effects. Pediatrics 1993; 91(6): 1101–6

    PubMed  CAS  Google Scholar 

  31. Fine S, Johnston C. Drug and placebo side effects in methylphenidate-placebo trial for attention deficit hyperactivity disorder. Child Psychiatry Hum Dev 1993; 24(1): 25–30

    Article  PubMed  CAS  Google Scholar 

  32. Barkley RA, McMurray MB, Edelbrock CS, et al. Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation. Pediatrics 1990; 86(2): 184–92

    PubMed  CAS  Google Scholar 

  33. Cantwell DP. Attention deficit disorder: a review of the past 10 years. J Am Acad Child Adolesc Psychiatry 1996; 35(8): 978–87

    Article  PubMed  CAS  Google Scholar 

  34. Dyme IZ, Sahakian BJ, Golinko, et al. Perseveration induced by methylphenidate in children: preliminary findings. Prog Neuropsychopharmacol Biol Psychiatry 1982; 6: 269–73

    Article  PubMed  CAS  Google Scholar 

  35. Douglas VI, Barr RG, Desilets J, et al. Do high doses of stimulants impair flexible thinking in attention-deficit hyperactivity disorder? J Am Acad Child Adolesc Psychiatry 1995; 34(7): 877–85

    Article  PubMed  CAS  Google Scholar 

  36. Johnston C, Pelham WE, Horz J. Psychostimulant rebound in attention deficit disordered boys. J Am Acad Child Adolesc Psychiatry 1988; 27: 806–10

    Article  PubMed  CAS  Google Scholar 

  37. Masand PS, Tesar GE. Use of stimulants in the medically ill. Psychiatr Clin North Am 1996; 19(3): 515–47

    Article  PubMed  CAS  Google Scholar 

  38. Wilens TE, Spencer T, Biederman J, et al. Combined pharmacotherapy: an emerging trend in pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry 1995; 34(1): 110–2

    Article  PubMed  CAS  Google Scholar 

  39. Pataki CS, Carlson GA, Kelly KL, et al. Side effects of methylphenidate and desipramine alone and in combination in children. J Am Acad Child Adolesc Psychiatry 1993; 32(5): 1065–72

    Article  PubMed  CAS  Google Scholar 

  40. Varley C, McClellan J. Case study: two additional suddendeaths with tricyclic antidepressants. J Am Acad Child Adolesc Psychiatry 1997; 36(3): 390–4

    Article  PubMed  CAS  Google Scholar 

  41. Swanson JR, Jones GR, Krasselt W, et al. Death of 2 subjects due to imipramine and desipramine metabolite accumulation during chronic therapy; a review of the literature and possible mechanisms. J Forensic Sci 1997: 42(2): 335–9

    PubMed  CAS  Google Scholar 

  42. Maloney M, Schwam J. Clonidine and sudden death. Pediatrics 1995; 96(6): 1176–7

    PubMed  CAS  Google Scholar 

  43. Parran TV, Jasinski DR. Intravenous methylphenidate abuse: prototype for prescription drug abuse. Arch Intern Med 1991; 151: 781–3

    Article  PubMed  Google Scholar 

  44. Jaffe SL. Intranasal abuse of prescribed methylphenidate by an alcohol and drug abusing adolescent with ADHD. J Am Acad Child Adolesc Psychiatry 1991; 30(5): 773–5

    PubMed  CAS  Google Scholar 

  45. Drug Enforcement Administration. Methylphenidate: review document. Drug and Chemical Evaluation Section, Office of Diversion Control, US Department of Justice, 1995

  46. CHADD Organization (Children and adults with attention deficit disorder) and the American Academy of Neurology. A petition to reclassify methylphenidate. Submitted to the Department of Justice, Oct 1994

  47. United States Pharmacopeia 23, National Formulary 18. United States Pharmacopeil Convention, Inc. Rockville, MD, 1995: 1861–88

  48. Johnson ISR, O’Malley P, Bechman J. National survey results on drug use for the monitoring the future study, 1975–1994: vol. 1. Secondary school students. Washington, DC: National Institute of Health, 1995: Rep. no. 95-4026

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics and Human Development, College of Human Medicine, Michigan State University, B-240 Life Science Building, East Lansing, Michigan, 48824, USA

    Marsha D. Rappley

Authors
  1. Marsha D. Rappley
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marsha D. Rappley.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rappley, M.D. Safety Issues in the Use of Methylphenidate. Drug-Safety 17, 143–148 (1997). https://doi.org/10.2165/00002018-199717030-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199717030-00001

Keywords

Search

Navigation